Page 121 - GTM-4-1

Global Translational Medicine AA amyloidosis in rheumatoid arthritis

Cl+/Cl- – – Cl+ Cl+ Cl+ 9 – – – – – – –

CoD rAAa-U rAAa-U rAAa-U rAAa-U rAAa-U 25 – – – – – – –

Severity (amount) in % 36.58 39.78 42.38 55.54 61.13 34 ND ND ND ND ND ND ND

Prevalence in % 75.00 87.50 87.50 100.0 100.0 34 ND ND ND ND ND ND ND

“+” n 3 7 7 7 6 34 ND ND ND ND ND ND ND

“0” n 1 1 1 0 0 34 ND ND ND ND ND ND ND

Avg of sAAa/Pt 1.097 1.193 1.271 1.666 1.834 34 21.75 0.64 0.447 0 34 100.00 21.322

Sum 4.389 9.547 10.17 11.66 11.00 34 ND ND ND ND ND ND ND

Count 4 8 8 7 6 34 ND ND ND ND ND ND ND

Avg of sAAa/Pt 1.097 1.193 1.271 1.666 1.834 34 21.75 0.64 0.447 0 34 100.000 21.322 amyloidosis (n=3) (322/81, 430/80, 45/74); in additional 5 (243/87, 287/91, 395/76, 245/88, 367/75) of 31 patients, cardiac amyloidosis contributed to the death; sAAa led to death in 25 of 34

Brain ND 0 0 ND ND 26 0.00 0.0 0.00 26 0 0.000 0.000 Notes: (i) Table 3 is organized based on increasing amounts of amyloid A (AA) deposits across eight organs (vertical: kidney, heart, pancreas, gastrointestinal [GI] tract, liver, lung, skin, brain) and (ii) Definitions: Pr. n 0] /y: Protocol number/year; Prevalence/patient in % (Prev. %): Positive (“+”) cases in % of “count”; Severity in % (Sev. %): “Avg” in % of maximum “3” value of s

Skin ND 0.2 0.5 0.8 ND 24 4.20 0.18 0.295 16 8 33.333 5.833

Lung 0.917 0.833 0.917 1.167 1.750 34 14.59 0.43 0.445 9 25 73.529 14.300

Liver 1.222 0.667 2.000 1.000 1.556 32 19.28 0.60 0.567 6 26 81.250 20.082

GI tract 0 1.53 1.42 1.83 1.38 31 23.05 0.74 0.505 2 29 93.548 24.785 increasing severity of AA deposits across 34 patients (horizontal: ordered by severity %/organ).

Pancreas ND 2.000 1.650 1.900 2.900 29 24.40 0.84 0.724 3 26 89.655 28.046 (v) Gastrointestinal amyloidosis did not play a direct role in the mortality of rheumatoid arthritis patients.

Heart ND 2.400 1.600 2.300 1.500 33 32.10 0.97 0.611 4 29 87.879 32.424

Kidney 2.250 1.917 2.083 2.667 1.917 33 32.67 0.99 0.783 4 29 87.879 32.998 (iii) Lethal outcome of sAAa was diagnosed clinically in 9 of 25 patients. (iv) AA deposits were not found in the brain.

Table 3. (Continued) Pr. n 0] /y f/m Serial number 237/70 F 101/90 F 255/83 F 53/87 M 181/80 M Statistics Count Sum Avg SD “0” “+” Prev.% Sev. % patients.

31
32
30
Volume 4 Issue 1 (2025) 33 34 113 doi: 10.36922/gtm.5325